biote Corp. (BTMD)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: liquidity fails both floors — 20-day average dollar volume ≈$357K is far below the $5M minimum and the recent 3-session regular-hour average ≈$137K is below the $1.5M recent-liquidity floor, so no entry type qualifies (a pullback/oversold limit is additionally countertrend: price below the SMA50 with MACD < 0 and under a declining SMA200 without a momentum reclaim; no breakout stop qualifies either, on the same liquidity failure).
Company overview
Biote Corp. specializes in hormone optimization for medical practices, offering a system for Biote-certified professionals to address hormone, vitamin, and mineral imbalances. The company provides bioidentical hormone treatments, dietary supplements, and sterile kits for hormone pellet insertion.
Fundamental
fairBiote's fundamentals are mixed, with low valuation multiples but high uncertainty due to recent recall and legal costs.
Recent SEC filings show BTMD coming off a profitable FY2025 but posting a markedly weaker 1H2026 tied to a voluntary recall and elevated legal costs (revenue down year-over-year and results swinging to a net loss). Liquidity includes ~$11.2M cash at 6/30/2026, a $125M term loan, and disclosed revolver capacity, with covenant compliance and no going‑concern language, but also negative equity and prior credit-agreement waiver history. Valuation multiples look very low (P/E ~6.3, EV/EBITDA ~4.6, EV/Sales ~1.0), yet the setup remains high‑uncertainty until revenue/margins and legal/regulatory noise stabilize.
Sentiment
fairSentiment is neutral, with insider buying balanced by recall-related concerns.
Executive-Chairman insider buying (announced, bullish) partially offsets a voluntary-recall overhang and a break-even Q2 print (both announced); media sentiment delta indeterminate after three baseline-extraction failures; moderate red-flag cap applied for conflicting catalyst signals (insider buying vs. recall).
Technical
weakTechnicals show a persistent downtrend with no clear entry point due to liquidity constraints.
BTMD closed Monday at 1.325 (−1.9%), just above its 52-week low of 1.27, in a persistent downtrend from ~2.26 in early August. Price sits below every moving average (SMA20 1.49, EMA9 1.38, EMA21 1.47, SMA50 1.77, SMA200 2.04) and below the session VWAP (1.33). Momentum remains negative: RSI14 36.5 (weak, not yet oversold), Williams %R −95 (deeply oversold but with no reversal trigger), MACD line/signal −0.11 with a flat histogram, ADX 24.9 (subdued trend strength, direction down). Volatility is high (ATR14 0.12 = 9.1% of price). Chart quality is bounce-only at best, so score 2.
You’re looking at 2026-09-21 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.